Koninklijke Philips NV's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $316 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $1,822 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Koninklijke Philips NV's annualizedROC % for the quarter that ended in Mar. 2026 was 3.53%.
Koninklijke Philips NV's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 40.67%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Koninklijke Philips NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.64%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Koninklijke Philips NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Koninklijke Philips NV EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Koninklijke Philips NV's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Koninklijke Philips NV's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,822 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Koninklijke Philips NV (RYLPF) has a EBIT of $1,822 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Koninklijke Philips NV.
Is Koninklijke Philips NV's EBIT too high?
Koninklijke Philips NV's current EBIT is $1,822 Mil. Overall, Koninklijke Philips NV has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's EBIT compare to ABT and SYK?
Koninklijke Philips NV's EBIT of $1,822 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Koninklijke Philips NV. Koninklijke Philips NV's current EBIT is $1,822 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $25.13, compared to a current price of $26.19 — trading 4.2% above its estimated fair value. The current EBIT is $1,822 Mil. Koninklijke Philips NV's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current EBIT is $1,822 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued.
The current stock price of $26.19 is trading 4.2% above its estimated GF Value™ of $25.13.
GuruFocus considers Koninklijke Philips NV to be Fairly Valued.
Key valuation signals for RYLPF:
EBIT: $1,822 Mil
GF Value™: $25.13 vs. price of $26.19 (4.2% above fair value)
No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
73GF Score
Get the complete analysis for RYLPF
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYLPF has been successfully added to your 
